论文部分内容阅读
目前,伊马替尼(imatinib mesylate,Gleevec/Glivec)是治疗慢粒的一线药物,属于ABL酪氨酸激酶抑制剂,是以ABL蛋白激酶的ATP结合位点为基础而设计合成。它通过抑制BCR-ABL自身磷酸化和底物磷酸化,而抑制细胞增殖和诱导凋亡。但随着临床
Currently, imatinib (imatinib mesylate, Gleevec / Glivec) is a first-line drug for the treatment of CML and is an ABL tyrosine kinase inhibitor designed and synthesized based on the ATP binding site of ABL protein kinase. It inhibits cell proliferation and induces apoptosis by inhibiting BCR-ABL autophosphorylation and substrate phosphorylation. But with clinical